AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress
